View More View Less
  • 1 Egyesített Szent István és Szent László Kórház Budapest Gyáli út 5–7. 1097
  • | 2 Budai Hepatológiai Centrum Budapest
  • | 3 Szent János Kórház és Észak-budai Egyesített Kórházak Hepatológiai Szakrendelés Budapest
  • | 4 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest
  • | 5 Debreceni Egyetem, Általános Orvostudományi Kar Belgyógyászati Intézet, Gasztroenterológiai Tanszék Debrecen
  • | 6 Pécsi Tudományegyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Pécs
  • | 7 Somogy Megyei Kaposi Mór Oktató Kórház Gasztroenterológiai Osztály Kaposvár
Open access

A Hepatitis Regiszter a Magyar Gasztroenterológai Társaság Hepatológiai Szekciója által a Májbetegekért Alapítvány közreműködésével létrehozott és üzemeltetett rendszer, amely a krónikus hepatitis B és C interferonalapú kezelésének nyilvántartására, valamint az engedélyezési folyamat elektronikus megvalósítására készült. A regiszter segítségével vált tisztázhatóvá a hepatitis C elleni új, hármas kezelésre várakozók száma és összetétele: 3000, korábban sikertelenül kezelt betegnél indokolt és lehetséges az újrakezelés, 40%-uknál a májbetegség már cirrhosis stádiumában van, és 40%-uk volt a korábbi kettős kezelésre nullreagáló. A rendszer a benyújtott IFN-alapú kezelési kérelmekhez automatikusan hozzárendeli a szakmai ajánlásban, illetve finanszírozási protokollban meghatározott prioritási indexet, ami a kezelés sürgősségének mérőszáma. Legfőbb meghatározója a fibrosis mértéke, de szerepelnek benne a betegség progressziójának mértékét, a gyógyhajlamot és speciális szempontokat tükröző összetevők is. Orv. Hetil., 2013, 154, 1151–1155.

  • Harris, H., Ramsay, M.: Hepatitis C in the UK. Health Protection Agency, 2011. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1309969906418

    Ramsay M. , '', in Hepatitis C in the UK , (2011 ) -.

  • Kramer, J. R., Kanwal, F., Richardson, P., et al.: Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J. Hepatol., 2012, 56, 320–325.

    Richardson P. , 'Gaps in the achievement of effectiveness of HCV treatment in national VA practice ' (2012 ) 56 J. Hepatol. : 320 -325.

    • Search Google Scholar
  • Jensen, D. M., Marcellin, P., Freilich, B., et al.: Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann. Intern. Med., 2009, 150, 528–540.

    Freilich B. , 'Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial ' (2009 ) 150 Ann. Intern. Med. : 528 -540.

    • Search Google Scholar
  • Fassio, E.: Hepatitis C and hepatocellular carcinoma. Ann. Hepatol., 2010, 9 (Suppl. 1), 119–122.

    Fassio E. , 'Hepatitis C and hepatocellular carcinoma ' (2010 ) 9 Ann. Hepatol. : 119 -122.

  • Sherman, K. E.: Advanced liver disease: what every hepatitis C virus treater should know. Top. Antivir. Med., 2011, 19, 121–125.

    Sherman K. E. , 'Advanced liver disease: what every hepatitis C virus treater should know ' (2011 ) 19 Top. Antivir. Med. : 121 -125.

    • Search Google Scholar
  • Masuzaki, R., Tateishi, R., Yoshida, H., et al.: Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. World J. Gastroenterol., 2012, 18, 1385–1390.

    Yoshida H. , 'Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography ' (2012 ) 18 World J. Gastroenterol. : 1385 -1390.

    • Search Google Scholar
  • Kim, S. U., Lee, J. H., Kim, do Y., et al.: Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One, 2012, 7, e36676.

    Kim do Y. , 'Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis ' (2012 ) 7 PLoS One : e36676 -.

    • Search Google Scholar
  • Castera, L., Pinzani, M., Bosch, J.: Non invasive evaluation of portal hypertension using transient elastography. J. Hepatol., 2012, 56, 696–703.

    Bosch J. , 'Non invasive evaluation of portal hypertension using transient elastography ' (2012 ) 56 J. Hepatol. : 696 -703.

    • Search Google Scholar
  • Motosugi, U., Ichikawa, T., Koshiishi, T., et al.: Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study. Eur. Radiol., 2013, 23, 156–162.

    Koshiishi T. , 'Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study ' (2013 ) 23 Eur. Radiol. : 156 -162.

    • Search Google Scholar
  • Sporea, I., Sirli, R. L., Deleanu, A., et al.: What did we learn from the first 3,459 cases of liver stiffness measurement by transient elastography (FibroScan®)? Ultraschall. Med., 2011, 32, 40–45.

    Deleanu A. , 'What did we learn from the first 3,459 cases of liver stiffness measurement by transient elastography (FibroScan®)? ' (2011 ) 32 Ultraschall. Med. : 40 -45.

    • Search Google Scholar
  • Pineda, J. A., Recio, E., Camacho, A., et al.: Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis. J. Acquir. Immune Defic. Syndr., 2009, 51, 445–449.

    Camacho A. , 'Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis ' (2009 ) 51 J. Acquir. Immune Defic. Syndr. : 445 -449.

    • Search Google Scholar
  • Vizzutti, F., Arena, U., Romanelli, R. G., et al.: Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology, 2007, 45, 1290–1297.

    Romanelli R. G. , 'Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis ' (2007 ) 45 Hepatology : 1290 -1297.

    • Search Google Scholar
  • Poordad, F., McCone, J. Jr., Bacon, B. R., et al.: Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, 364, 1195–1206.

    Bacon B. R. , 'Boceprevir for untreated chronic HCV genotype 1 infection ' (2011 ) 364 N. Engl. J. Med. : 1195 -1206.

    • Search Google Scholar
  • Jacobson, I. M., McHutchison, J. G., Dusheiko, G., et al.: Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med., 2011, 364, 2405–2416.

    Dusheiko G. , 'Telaprevir for previously untreated chronic hepatitis C virus infection ' (2011 ) 364 N. Engl. J. Med. : 2405 -2416.

    • Search Google Scholar
  • Bacon, B. R., Gordon, S. C., Lawitz, E., et al.: Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, 364, 1207–1217.

    Lawitz E. , 'Boceprevir for previously treated chronic HCV genotype 1 infection ' (2011 ) 364 N. Engl. J. Med. : 1207 -1217.

    • Search Google Scholar
  • Poordad, F., Bronowicki, J. P., Gordon, S. C., et al.: Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology, 2012, 143, 608–618.

    Gordon S. C. , 'Factors that predict response of patients with hepatitis C virus infection to boceprevir ' (2012 ) 143 Gastroenterology : 608 -618.

    • Search Google Scholar
  • Zeuzem, S., Andreone, P., Pol, S., et al.: Telaprevir for retreatment of HCV infection. N. Engl. J. Med., 2011, 364, 2417–2428.

    Pol S. , 'Telaprevir for retreatment of HCV infection ' (2011 ) 364 N. Engl. J. Med. : 2417 -2428.

    • Search Google Scholar
  • Chhatwal, J., Roberts, M. S., Dunn, M. A., et al.: Prioritization of chronic hepatitis C patients for treatment with direct-acting antiviral agents. American Association for the Study of Liver Diseases Annual Meeting 2012. Abstract ID 152

  • Boceprevir for the treatment of genotype 1 chronic hepatitis C. National Institute for Health and Clinical Excellence. Technology appraisal guidance 253. http://www.nice.org.uk/nicemedia/live/13718/58913/58913.pdf

  • Chhatwal, J., Ferrante, S. A., Dasbach, E. J., et al.: Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin. Hepatology, 2011, 54 (Suppl. 1), 801A–802A.

    Dasbach E. J. , 'Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin ' (2011 ) 54 Hepatology : 801A -802A.

    • Search Google Scholar
  • Wyles, D. L.: Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top. Antivir. Med., 2012, 20, 139–145.

    Wyles D. L. , 'Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection ' (2012 ) 20 Top. Antivir. Med. : 139 -145.

    • Search Google Scholar
  • Puoti, M., Rossotti, R., Travi, G., et al.: Top topics in HCV research arena. BMC Infect. Dis., 2012, 12 (Suppl. 2), S7.

    Travi G. , 'Top topics in HCV research arena ' (2012 ) 12 BMC Infect. Dis. : S7 -.

  • Osborn, M. K.: Highlights of the 2012 American Association for the Study of Liver Diseases meeting. Top. Antivir. Med., 2012, 20, 180–184.

    Osborn M. K. , 'Highlights of the 2012 American Association for the Study of Liver Diseases meeting ' (2012 ) 20 Top. Antivir. Med. : 180 -184.

    • Search Google Scholar
  • Aronsohn, A., Jensen, D.: Distributive justice and the arrival of direct-acting antivirals: Who should be first in line? Hepatology, 2011, 53, 1789–1791.

    Jensen D. , 'Distributive justice and the arrival of direct-acting antivirals: Who should be first in line? ' (2011 ) 53 Hepatology : 1789 -1791.

    • Search Google Scholar
  • Ford, N., Singh, K., Cooke, G. S., et al.: Expanding access to treatment for hepatitis C in resource-limited settings: Lessons from HIV/AIDS. Clin. Infect. Dis., 2012, 54, 1465–1472.

    Cooke G. S. , 'Expanding access to treatment for hepatitis C in resource-limited settings: Lessons from HIV/AIDS ' (2012 ) 54 Clin. Infect. Dis. : 1465 -1472.

    • Search Google Scholar
  • Russo, M. W.: Current concepts in the evaluation of patients for liver transplantation. Expert Rev. Gastroenterol. Hepatol., 2007, 1, 307–320.

    Russo M. W. , 'Current concepts in the evaluation of patients for liver transplantation ' (2007 ) 1 Expert Rev. Gastroenterol. Hepatol. : 307 -320.

    • Search Google Scholar
  • Ghany, M. G., Nelson, D. R., Strader, D. B., et al.: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011, 54, 1433–1444.

    Strader D. B. , 'An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases ' (2011 ) 54 Hepatology : 1433 -1444.

    • Search Google Scholar
  • Ramachandran, P., Fraser, A., Agarwal, K., et al.: UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment. Pharmacol. Ther., 2012, 35, 647–662.

    Agarwal K. , 'UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients ' (2012 ) 35 Aliment. Pharmacol. Ther. : 647 -662.

    • Search Google Scholar
  • McEwan, P., Kim, R., Yuan, Y.: Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl. Health Econ. Health Policy, 2013, 11, 53–63.

    Yuan Y. , 'Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model ' (2013 ) 11 Appl. Health Econ. Health Policy : 53 -63.

    • Search Google Scholar
  • Liu, S., Cipriano, L. E., Holodniy, M., et al.: New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann. Intern Med., 2012, 156, 279–290.

    Holodniy M. , 'New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis ' (2012 ) 156 Ann. Intern Med. : 279 -290.

    • Search Google Scholar
  • Williams, M. J., Lang-Lenton, M., Trent HCV Study Group: Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J. Viral. Hepat., 2011, 18, 17–22.

    Lang-Lenton M. , 'Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection ' (2011 ) 18 J. Viral. Hepat. : 17 -22.

    • Search Google Scholar
  • Terrault, N. A., Im, K., Boylan, R., et al.: Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin. Gastroenterol. Hepatol., 2008, 6, 1403–1411.

    Boylan R. , 'Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C ' (2008 ) 6 Clin. Gastroenterol. Hepatol. : 1403 -1411.

    • Search Google Scholar
  • Poordad, F., Bronowicki, J. P., Gordon, S. C., et al.: Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology, 2012, 143, 608–618.e1–5.

    Gordon S. C. , 'Factors that predict response of patients with hepatitis C virus infection to boceprevir ' (2012 ) 143 Gastroenterology : 608 -618.e1–5.

    • Search Google Scholar
  • Kwo, P. Y.: Phase III results in genotype 1 naive patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver. Int., 2012, 32 (Suppl. 1), 39–43.

    Kwo P. Y. , 'Phase III results in genotype 1 naive patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin ' (2012 ) 32 Liver. Int. : 39 -43.

    • Search Google Scholar
  • Chayama, K., Hayes, C. N., Abe, H., et al.: IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J. Infect. Dis., 2011, 204, 84–93.

    Abe H. , 'IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C ' (2011 ) 204 J. Infect. Dis. : 84 -93.

    • Search Google Scholar
  • Berg, T., Andreone, P., Pol, S., et al.: Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: Post-hoc analysis of the phase III REALIZE study. Hepatology, 2011, 54, 375A–376A.

    Pol S. , 'Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: Post-hoc analysis of the phase III REALIZE study ' (2011 ) 54 Hepatology : 375A -376A.

    • Search Google Scholar
  • Hezode, C., Dorival, C., Zoulim, F., et al.: Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC). J. Hepatol., 2012, 56, S4–S5.

    Zoulim F. , 'Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) ' (2012 ) 56 J. Hepatol. : S4 -S5.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 85 81 2
PDF Downloads 25 24 2